Previous close | 0.7592 |
Open | 0.7838 |
Bid | 0.7778 x 1500000 |
Ask | 0.8190 x 1500000 |
Day's range | 0.7838 - 0.7838 |
52-week range | 0.6226 - 0.8842 |
Volume | |
Avg. volume | 3,513 |
Market cap | 9.59B |
Beta (5Y monthly) | 0.70 |
PE ratio (TTM) | 13.06 |
EPS (TTM) | 0.0600 |
Earnings date | 27 May 2024 |
Forward dividend & yield | 0.03 (4.34%) |
Ex-dividend date | 31 May 2024 |
1y target est | N/A |
China's vaccine developers stuck with unused mRNA COVID shots and idle manufacturing plants are pursuing new targets for the novel messenger RNA technology, but they face a tough path, crimped by a lack of revenue. Three Chinese companies - Walvax Biotechnology, CSPC Pharmaceutical Group and Stemirna Therapeutics - came up with mRNA vaccines that won limited emergency approvals in Asia. However, Walvax and CSPC are not currently manufacturing three of their China market shots, a China health official told Reuters.
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, together with CSPC Pharmaceutical Group Limited (CSPC; HKEX: 01093), today announced promising initial clinical data for SYSA1801 (EO-3021) from the ongoing Phase 1 dose escalation and expansion study in China. These data will be presented at the American Society of Cli